Title : Novel SLC12A2-ROS1 Fusion in Non-Small Cell Lung Cancer with a Significant Response to Crizotinib: The Importance of Choosing the Appropriate Next-Generation Sequencing Assay.

Pub. Date : 2021 Jun

PMID : 33682977






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Novel SLC12A2-ROS1 fusion in non-small-cell lung cancer with a significant response to crizotinib: the importance of choosing the appropriate next-generation sequencing assay. Crizotinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens
2 We describe a novel SLC12A2-ROS1 rearrangement that has not been previously reported in other cancers, a fusion that has clinical and radiological sensitivity to crizotinib. Crizotinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens
3 Given our patient"s response to crizotinib, identifying patients with undescribed ROS1 fusions has important therapeutic implications. Crizotinib ROS proto-oncogene 1, receptor tyrosine kinase Homo sapiens